Trial | NCT00689195  Report issue

Title

Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma
Evaluation of Curcumin Formulation, and Ashwagandha Root Powder Extract in the Management of Advanced High Grade Osteosarcoma"

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    24
Curcumin as well as the ashwagandha extract are ingredients from traditional indian medicine and have been shown to be potent anti-cancer compounds in laboratory as well as animal studies. This study will test the safety and efficacy of a curcumin formulation and the ashwagandha extract in high grade relapsed or metastatic osteosarcoma where no other second line chemotherapy is being given. The pharmacokinetics will be studied along with response as measured on CT scans and PET scans as well as the quality of life and any toxicity.
Eligibility criteria

Osteosarcoma which has relapsed after treatment and for which no second line chemotherapy is planned and in which disease is not amenable to surgery.
Patient should be able to follow-up 3 monthly for clinical and imaging assessment as well as biochemical tests
Study Started
May 31
2008
Primary Completion
Jun 30
2013
Anticipated
Study Completion
Jun 30
2013
Anticipated
Last Update
Jun 23
2011
Estimate

Dietary Supplement Curcumin powder

oral capsules containing the investigational agent

  • Other names: M3CX,

Dietary Supplement Ashwagandha extract

4.5% extract of ashwagandha

  • Other names: Withania somnifera,, Dunal,, Indian Ginseng

C Experimental

Curcumin

A Experimental

Ashwagandha extract

Criteria 

Inclusion Criteria:

Patients (between the ages of 8 to 65 years) with histologically proven high grade osteosarcoma of the extremity and relapsed disease after primary line of treatment who are unsuitable or refuse secondary chemotherapy.
Patients with advanced disease unable or unwilling to take primary conventional treatment
Patients with early or non-metastatic disease who are unable or unwilling to take the standard chemotherapy.
Adequate hepatic function defined by total bilirubin not more than 1.5 times the upper limit of normal (ULN) and SGOT and SGPT not more than 2.5 times the (ULN)
Adequate renal function defined by the creatinine clearance greater than 50 ml/min, calculated by cockcroft-Gault formula

Exclusion Criteria:

Patients who are suitable for second line chemotherapy and can afford it
Age less than 8 years or greater than 65 years
Pregnant or lactating women
Patients who are unable or unwilling to provide blood samples for the drug assays.
Low grade osteosarcoma
Patient requiring treatment with CYP3A4 inducers or inhibitors (patients on treatment for epilepsy or tuberculosis)
Participation in any investigational drug study within 28 days prior to study treatment.
No Results Posted